302 related articles for article (PubMed ID: 24664624)
1. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Konstantinidis IT; Do RK; Gultekin DH; Gönen M; Schwartz LH; Fong Y; Allen PJ; D'Angelica MI; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Ann Surg Oncol; 2014 Aug; 21(8):2675-83. PubMed ID: 24664624
[TBL] [Abstract][Full Text] [Related]
2. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
3. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
Jarnagin WR; Schwartz LH; Gultekin DH; Gönen M; Haviland D; Shia J; D'Angelica M; Fong Y; DeMatteo R; Tse A; Blumgart LH; Kemeny N
Ann Oncol; 2009 Sep; 20(9):1589-1595. PubMed ID: 19491285
[TBL] [Abstract][Full Text] [Related]
4. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
5. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
6. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?
Kemeny NE; Schwartz L; Gönen M; Yopp A; Gultekin D; D'Angelica MI; Fong Y; Haviland D; Gewirtz AN; Allen P; Jarnagin WR
Oncology; 2011; 80(3-4):153-9. PubMed ID: 21677464
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Holster JJ; El Hassnaoui M; Franssen S; IJzermans JNM; de Jonge J; Mostert B; Polak WG; de Wilde RF; Homs MYV; Groot Koerkamp B
Ann Surg Oncol; 2022 Sep; 29(9):5528-5538. PubMed ID: 35294656
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
12. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
Kasai K; Kooka Y; Suzuki Y; Suzuki A; Oikawa T; Ushio A; Kasai Y; Sawara K; Miyamoto Y; Oikawa K; Takikawa Y
Ann Surg Oncol; 2014 Oct; 21(11):3638-45. PubMed ID: 24817369
[TBL] [Abstract][Full Text] [Related]
14. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.
Massani M; Nistri C; Ruffolo C; Bonariol R; Pauletti B; Bonariol L; Caratozzolo E; Morana G; Bassi N
Updates Surg; 2015 Dec; 67(4):389-400. PubMed ID: 26468142
[TBL] [Abstract][Full Text] [Related]
17. Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging.
Hahn F; Müller L; Jungmann F; Mähringer-Kunz A; Tanyildizi Y; Düber C; Galle PR; Weinmann A; Kloeckner R
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1883-1890. PubMed ID: 32232655
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhao R; Zhou J; Miao Z; Xiong X; Wei W; Li S; Guo R
Front Immunol; 2024; 15():1397827. PubMed ID: 38799453
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Hyder O; Marsh JW; Salem R; Petre EN; Kalva S; Liapi E; Cosgrove D; Neal D; Kamel I; Zhu AX; Sofocleous CT; Geschwind JF; Pawlik TM
Ann Surg Oncol; 2013 Nov; 20(12):3779-86. PubMed ID: 23846786
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]